Latest Humira biosimilar settlement provides further proof of AbbVie patent strategy’s effectiveness

Latest Humira biosimilar settlement provides further proof of AbbVie patent strategy’s effectiveness

With the recent announcement that it had reached a settlement in its patent dispute with Samsung Bioepis, AbbVie has scored another significant victory in efforts to delay market entry to biosimilar versions of its drug, Humira. While allowing…

Unlock unlimited access to all IAM content